AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

Through the Mango partnership, Veeda will use the AI company’s Querent platform to streamline procedures, improve data management and increase diversity of research participants, according to a July 8 ...

At the halfway mark last year, 97 layoff rounds were reported, marking a 32% year-over-year increase for the first half of ...

Taiho-developed TAS-205 is designed to selectively inhibit hematopoietic prostaglandin D synthase (HPGDS), an enzyme related ...

The FDA has cleared its first cuffless blood pressure monitor that will be available over-the-counter, with the Hilo ...

Cargo will mark the latest in a string of acquisitions for the deal-hungry Concentra. So far this year, Concentra has signed ...

KJ Muldoon recently made history by becoming the first patient to receive a personalized CRISPR gene therapy, designed specifically for the genetic mutations causing his rare metabolic disease. | KJ ...

Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which obtained a groundbreaking FDA clearance late last year. | LumiThera's approach ...

At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

Following long-time chief José Almeida’s retirement earlier this year, Baxter announced it has officially named a new CEO. | ...

Headlands Research, a clinical trial site network with locations across the U.S. and Canada, has made its first step into the ...